Clinical trials: IV Access
Patients in Need for Intravenous Access
Evaluation of Introcan Safety 3 Closed IV Catheter
Incidence and time of occurrence of blood leakage with the closed intravascular catheter Introcan Safety 3 in comparison to Introcan Safety
- Trial name
- NCT02197013
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- B. Braun Melsungen AG
ALK Positive Malignancies
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with…
- Trial name
- NCT02584933
- Testing
- ceritinib
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Airway Control
Rapid Sequence Intubation Drug Delivery Using Intraosseous and IV Access in Pediatric Patients Observational Study
This study will evaluate using intraosseous vascular access and intravenous vascular access to give pediatric patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01634867
- Where
- United States
- Sponsor
- Vidacare Corporation
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
- Trial name
- NCT03424473
- Testing
- Tucatinib
- Sponsor
- Seagen Inc.
Peripheral Venous Catheterization, Difficult Intravenous Access
TruVascular Access - Ultrasound-Guided Vascular Access Study
TruVascular Access - TVA-2026 is a prospective, randomized clinical study evaluating whether ultrasound-guided peripheral vascular access improves first-attempt cannulation success compared with conventional landmark…
- Conditions
- Peripheral Venous Catheterization, Difficult Intravenous Access, Catheterization, Peripheral
- Trial name
- TVA-2026 (NCT07798427)
- Testing
- Ultrasound-Guided Peripheral Vascular Access, Standard Peripheral Vascular Access, Point-of-Care Ultrasound System for Vascular Access Guidance
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Truway Health, Inc.
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
- Trial name
- NCT04264884
- Testing
- Daratumumab
- Sponsor
- Janssen Research & Development, LLC
Melanoma
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
The primary objective of the study is to provide treatment with Ipilimumab to subjects who have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who have no alternative treatment options, and…
- Trial name
- NCT00495066
- Testing
- Ipilimumab
- Where
- 9 sites in Brazil
- Sponsor
- Bristol-Myers Squibb
Intravenous Access According to Instructions For Use
Study Comparing the Handling of Two Peripheral IV Catheter Systems
A peripheral intravenous catheter is the most commonly used vascular access device in medicine. Primary objective is to compare insertion and handling of two peripheral intravenous catheters in clinical routine.
- Trial name
- NCT02213965
- Testing
- Peripheral IV catheter
- Where
- 2 sites in Germany
- Volunteers
- 2,340 people
- Sponsor
- B. Braun Melsungen AG
Steroid Resistant Acute Graft Versus Host Disease
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in…
- Trial name
- NCT05047328
- Testing
- inolimomab
- Where
- France
- Sponsor
- ElsaLys Biotech
Mucopolysaccharidosis IVA, Morquio A Syndrome
BMN 110 US Expanded Access Program
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01858103
- Testing
- BMN 110
- Where
- 25 sites in United States, Puerto Rico
- Sponsor
- BioMarin Pharmaceutical